Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-123375
Filing Date
2024-11-07
Accepted
2024-11-07 16:15:52
Documents
66
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q achv-20240930.htm   iXBRL 10-Q 2224153
2 EX-10.3 achv-ex10_3.htm EX-10.3 97997
3 EX-10.4 achv-ex10_4.htm EX-10.4 112991
4 EX-31.1 achv-ex31_1.htm EX-31.1 10697
5 EX-32.1 achv-ex32_1.htm EX-32.1 6073
  Complete submission text file 0000950170-24-123375.txt   8938713

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT achv-20240930.xsd EX-101.SCH 1309614
69 EXTRACTED XBRL INSTANCE DOCUMENT achv-20240930_htm.xml XML 1392595
Mailing Address 22722 29TH DR. SE SUITE 100 SEATTLE WA 98021
Business Address 22722 29TH DR. SE SUITE 100 SEATTLE WA 98021 425-686-1500
ACHIEVE LIFE SCIENCES, INC. (Filer) CIK: 0000949858 (see all company filings)

EIN.: 954343413 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 033-80623 | Film No.: 241435983
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)